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Background: CRTC1 (CREB regulated transcription coactivator 1) gene plays a role in synaptic plasticity, learning
and long-term memory formation in the hippocampus. Recently, CRTC1 has been shown to be downregulated in
Alzheimer’s disease (AD). Nevertheless, the mechanisms underlying CRTC1 dysregulation in AD remain unclear.
Methods: To understand better the epigenetic mechanisms regulating CRTC1 expression that may be altered in
AD, we profiled DNA methylation at CpG site resolution by bisulfite cloning sequencing in two promoter regions
(referred to as Prom1 and Prom2) of the CRTC1 gene in human hippocampus from controls and AD cases. Next, we
correlated DNA methylation levels with AD-related pathology, i.e., β-amyloid and phosphorylated-tau (p-tau) burden
and also measured CRTC1 mRNA levels by RT-qPCR.
Results: Methylation levels were lower in AD cases as compared to controls within both promoter regions (Prom1:
0.95 % vs. 5 %, p-value < 0.01 and Prom2: 2.80 % vs. 17.80 %, p-value < 0.001). Interestingly, CRTC1 methylation levels
inversely correlated with AD-related neuropathological changes, particularly with p-tau deposition (rSpearman = -0.903,
p < 0.001). Moreover, a 1.54-fold decrease in CRTC1 mRNA levels was observed in hippocampus of AD cases
compared to controls (p < 0.05) supporting the notion that CRTC1 is downregulated in the AD hippocampus.
Conclusions: DNA methylation levels within two distinct promoter regions of the CRTC1 gene were decreased in
human hippocampus affected by AD compared with controls and methylation within Prom1 showed a strong
inverse correlation with p-tau deposition. Further studies are guaranteed to elucidate the precise role that CRTC1
methylation plays in AD pathophysiology.
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CRTC1 (CREB regulated transcription coactivator 1)
[EMBL: BC017075] plays a critical role as coactivator of
the CREB (cAMP-responsive element binding)-dependent
gene transcription pathway [1], which in turn is essential
to synaptic plasticity, learning and long-term memory for-
mation in the hippocampus [2–7]. CRTC1 is highly
expressed in brain, particularly in hippocampal neurons
[8, 9], where it translocates from synapses and dendrites* Correspondence: maitemendilab@gmail.com
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(http://creativecommons.org/publicdomain/zeto the nucleus upon the concomitant activation of calcium
and cAMP signaling pathways [6, 10, 11]. Moreover, it has
been shown that CRTC1 is involved in dendritic growth of
developing cortical neurons [12]. The relevance of this
gene to brain function is additionally supported by experi-
ments performed on knockout mouse models. Mice lack-
ing Crtc1 develop psychomotor retardation along with
neurobehavioral endophenotypes. Interestingly, these mice
show reduced dopamine and serotonin turnover in the
prefrontal cortex and decreased expression of several
downstream genes involved in neuroplasticity [13]. In
addition, CRCT1 was recently identified as a modulator of
mitochondrial metabolism and longevity [14, 15].ticle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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date to be examined in neurodegenerative disorders at
the molecular level [16]. Indeed, the role of CRCT1 in
Alzheimer’s disease (AD) has been previously studied
in mouse models. Gene transcription mediated by
CRTC1 is impaired in neurons and brain from APP
(Sw, Ind) transgenic mice, an AD mouse model overex-
pressing the human β-amyloid precursor protein (APP)
[PDB: E9PG40] carrying human mutations [17, 18]. Re-
markably, β-amyloid-induced spatial learning and
memory deficits in APP (Sw, Ind) transgenic mice are
reversed by restoring a specific subset of CRTC1 target
genes [19]. However, studies performed on postmortem
human brain samples are still very scarce. In this re-
gard, a recent report shows that CRTC1-dependent
genes and CRTC1 protein [PDB: Q6UUV9] levels are
significantly reduced in human hippocampus at inter-
mediate and advanced (IV-VI) Braak pathological stages
[19]. Nevertheless, the specific mechanisms underlying
CRTC1-dependent gene transcriptional disruption in
AD still remain unclear.
DNA methylation is a widely studied epigenetic
mechanism that contributes to regulate gene expres-
sion. The addition of a methyl group to the 5-carbon
position of the cytosine-phosphate-guanine (CpG)
sites, mostly located at regulatory elements in the gen-
ome, modulates the transcription of nearby or related
genes. Interestingly, DNA methylation patterns change
during the ageing process [20–22] and may have an
impact on gene expression in the human brain [23]. In
addition, aberrant DNA methylation patterns are in-
volved in an increasing number of common diseases
[24, 25], including neurodegenerative conditions.
Based on that evidence, we hypothesized that certain
regulatory elements of the CRTC1 gene may be differ-
entially methylated in the hippocampus of AD pa-
tients. Hence, we aimed to profile DNA methylation
levels by bisulfite cloning sequencing in two distinct
promoter regions of CRTC1 in hippocampal samples
from a cohort of neuropathologically defined “pure”
AD cases and controls. We also explored the relationship
between DNA methylation levels and AD-related neuro-
pathological changes. Next, CRTC1 mRNA expression
was assessed in AD and control hippocampus.
Methods
Human brain samples
We conducted an observational, case-control study com-
paring postmortem hippocampal samples from AD patients
and control hippocampus. Frozen postmortem hippocam-
pal samples from 30 Alzheimer’s disease (AD) cases and 12
controls were provided by the Navarrabiomed Brain Bank.
After death, half brain specimens from donors were cryo-
preserved at −80 °C.Immunostaining protocol
Formalin-fixed (4 %), paraffin-embedded tissue from
mid-hippocampus region was cut (5-mm sections) and
placed on StarFrost Microscope Slides. After deparaffi-
nizing, endogenous peroxidase activity was quenched by
incubation with 0.3 % (vol/vol) H2O2 in methanol for
30 minutes at room temperature. Antigen retrieval was
performed by soaking the sections in 10-mM citrate buf-
fer pH 6.0, heated and boiled for 10 minutes in a micro-
wave oven.
Assessment of β-amyloid deposition was carried out
with a mouse monoclonal (S6F/3D) anti β-amyloid anti-
body (Leica Biosystems Newcastle Ltd, Newcastle upon
Tyne, UK) which identified the presence of amyloid
pathology.
Evaluation of neurofibrillary pathology was performed
with a mouse monoclonal antibody anti-human PHF-TAU,
clone AT-8, (Tau AT8) (Innogenetics, Ghent, Belgium),
which identified hyperphosphorylated tau (p-tau) [26] in
the shape of dystrophic neurites and neurofibrillary tangles.
The reaction product was visualized using an automated
slide immunostainer (Leica Bond Max) with Bond Polymer
Refine Detection (Leica Biosystems, Newcastle Ltd). Omis-
sion of the primary antibody was used as a negative control
for all stainings.
Neuropathological assessment
Neuropathological examination was completed follow-
ing the usual recommendations [27] and assessment of
AD was performed according to the updated National
Institute on Aging-Alzheimer's Association guidelines
[26]. Samples were further classified, based on the
ABC score, into four groups: control (n = 12), initial
AD (including A1B1C1, A1B2C1, A1B2C2, and
A1B2C3 scores) (n = 9), intermediate AD (including
A2B2C2, A2B2C3, and A2B3C3 scores) (n = 7) and ad-
vanced AD (including A3B2C1, A3B2C3, A3B3C2, and
A3B3C3 scores) (n = 14) (Additional file 1: Figure S1).
Importantly, to avoid spurious associations, those in-
dividuals showing coexisting protein deposits different
from p-tau or β-amyloid were not eligible for the
study. This approach maximizes chances of finding
true associations with AD, even though reducing the
final sample size. Neuropathological and demographic
features of subjects, including age, gender, ABC score
and postmortem interval are listed in Additional file 2:
Table S1.
Quantitative assessment of β-amyloid and p-tau deposits
in brain tissues
In order to quantitatively assess the β-amyloid and p-tau
burden for further statistical analysis we applied a
method to quantify protein deposits. This method gener-
ates a numeric measurement that reflects the extent of
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hippocampus were examined after performing immuno-
staining with anti β-amyloid and anti p-tau antibodies as
described above. Three pictures were obtained for each
immunostained section using an Olympus BX51 micro-
scope at 10x magnification power. Morphological de-
posits of β-amyloid, as described by Braak and Braak
(neuritic, immature and compact plaque), were manually
determined and those areas were further edited and ana-
lyzed with ImageJ software [28] (Additional file 1: Figure
S2). Next, β-amyloid plaque count referred to as amyloid
plaque score (APS) and total area of β-amyloid depos-
ition were automatically measured by ImageJ and aver-
aged for each section. Regarding p-tau deposit, pictures
were also analyzed with ImageJ software, by adjusting in
the threshold color hue (maximum range: 45–197), sat-
uration (maximum range: 7–243) and brightness (max-
imum range: 50–195), in order to obtain an averaged
quantitative measure of the global p-tau deposit for each
section (Additional file 1: Figure S2).
CRTC1 methylation profiling by bisulfite cloning
sequencing
Genomic DNA was isolated from hippocampal tissue by
standard methods [29]. Next, 500 ng of genomic DNA
was bisulfite converted using the EpiTect Bisulfite Kit
(QIAGEN, Redwood City, CA, USA) according to the
manufacturer’s instructions. Two promoter regions
(Prom1 and Prom2) within the CRTC1 gene were ampli-
fied by PCR (Additional file 1: Figure S3). Genomic co-
ordinates were obtained from GRCh37/Hg19 assembly.
Primer pair sequences were designed by MethPrimer
[30] and are listed in Additional file 2: Table S2. PCR
products were cloned using the TopoTA Cloning System
(Invitrogen, Carlsbad, CA, USA) and a minimum of 12
independent clones were sequenced for each examined
subject and region. Methylation graphs were obtained
with the QUMA software [31].
CRTC1 mRNA expression analysis
Total RNA was isolated from the 42 hippocampus ho-
mogenates using RNeasy Lipid Tissue Mini kit (QIA-
GEN, Redwood City, CA, USA), following the
manufacturer’s instructions. Genomic DNA was re-
moved with recombinant DNase (TURBO DNA-free™
Kit, Ambion, Inc., Austin, TX, USA). RNA integrity was
checked by 1.25 % agarose gel electrophoresis under de-
naturing conditions. Concentration and purity of RNA
were both evaluated with a NanoDrop spectrophotom-
eter. Only RNA samples showing a minimum quality
index (260 nm/280 nm absorbance ratios between 1.8
and 2.2 and 260 nm/230 nm absorbance ratios higher
than 1.8) were included in the study. Complementary
DNA (cDNA) was reverse transcribed from 1500 ngtotal RNA with SuperScript® III First-Strand Synthesis
Reverse Transcriptase (Invitrogen, Carlsbad, CA, USA)
after priming with oligo-d (T) and random primers. RT-
qPCR reactions were performed in triplicate with Power
SYBR Green PCR Master Mix (Invitrogen, Carlsbad,
CA, USA) in an Applied 7300 Real-Time PCR System
(Applied Biosystems, Foster City, CA, USA). Sequences
of primer pair were designed using the Real Time PCR
tool (IDT, Coralville, IA, USA) and are listed in
Additional file 2: Table S2. Relative expression level of
CRTC1 mRNA in a particular sample was calculated as
previously described [32] and the geometric mean of
GAPDH and ACTB genes were used to normalize ex-
pression values.
Statistical data analysis
Statistical analysis was performed with SPSS 21.0 (IBM,
Inc., USA). Data represent the mean ± SEM or median
(range), depending on the type of variable. Differences
with p-value < 0.05 were considered significant. Statis-
tical significance for expression and bisulfite intergroup
differences were assessed by the Mann-Whitney U test
and the Kruskal–Wallis test. Spearman’s rank correlation
coefficient was used to determine correlation between
AD-related pathology and methylation levels. When
multiple comparisons were performed, as was the case
of correlation between methylation levels and AD-
related pathological burden, a Bonferroni correction was
applied and the significance threshold was set at p-
corrected value = 0.008. GraphPad Prism version 6.00 for
Windows (GraphPad Software, La Jolla, CA, USA) was
used to draw the graphs except for methylation figures
that were obtained by QUMA software.
Ethics, consent and permissions
Our study was carried out in accordance with the
Declaration of Helsinki and handling of human brain
samples was performed according to the current Spanish
national legislation (Law 14/2007 and Royal Decree
RD1716/2011). The Ethics Committee of the “Complejo
Hospitalario de Navarra” approved the use of human
subjects for this study (90/2014). Written informed con-
sent was obtained from all subjects or next of kin, previ-
ous to brain donation, to perform research projects
related to neurodegenerative conditions. The consent
form is held by the authors’ institution and is available
for review by the Editor-in-Chief.
Results
CRTC1 methylation is decreased in hippocampus of AD
cases compared to controls
To begin to ask whether DNA methylation within CRTC1
is altered in AD hippocampus, two different promoters of
the CRTC1 gene were examined by bisulfite cloning
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immunoprecipitation sequencing (ChIP-seq) data from
the track Chromatin State Segmentation by HMM
(Hidden Markov Model) from ENCODE project and Broada
b
c
Fig. 1 DNA methylation levels within two promoter regions of CRTC1 in Al
genomic position of the two amplicons (Prom1 and Prom2) within the two
cloning sequencing. At the bottom of the graph, predicted functional elem
chromatin immunoprecipitation (ChIP) combined with massively parallel D
(yellow), transcriptional transition and elongation (dark green) and weak tra
green boxes. The track was obtained from Chromatin State Segmentation b
Browser. Next, dot plot charts and representative examples of the methylat
decrease in methylation was observed within both promoters in AD hippo
represent median methylation values for each group. Boxes on the right rep
and unmethylated cytosines, respectively. Each column symbolizes a uniqu
individual DNA clone. *p-value < 0.05; ** p-value < 0.005. CpG cytosine-phosInstitute, shown at the UCSC Genome Browser [33]. This
track displays chromatin state segmentation data for
each of nine human cell types (Fig. 1a, Additional file 1:
Figure S3). We designed primers to amplify twozheimer’s disease (AD) and control hippocampus. a The graph shows
promoter regions of the CRTC1 gene that were examined by bisulfite
ents are shown for each of nine human cell lines explored by
NA sequencing. Boxes represent promoter regions (red), enhancers
nscribed regions (light green). CpG islands are also represented by
y HMM from ENCODE/Broad track shown at the UCSC Genome
ion graphs for Prom1 (b) and Prom2 (c), respectively, are shown. A
campus compared to controls. Horizontal lines within dot plots
resent individual patients. Black and white circles denote methylated
e CpG site in the examined amplicon and each line represents an
phate-guanine
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was placed at the 5’ end of CRTC1, partially overlapping
exon 1 and the beginning of intron 1, and contained 37
CpG sites within the southern shore of a 628 bp-CpG is-
land (chr19:18794192–18794819). Whereas promoter 2
(Prom2) amplicon was located within intron 1 and
encompassed 15 CpG sites at the southern shore of a 230
bp-CpG island (chr19:18811562–18811791) (Fig. 1a,
Additional file 1: Figure S3). To sum up, a total of 52 indi-
vidual CpG sites, representing 63.8 % and 88.2 % of each
CpG island, respectively, were analyzed in a subset of five
control and eight AD cases. To calculate the average
methylation level, DNA methylation percentage was mea-
sured at CpG site resolution and further averaged across
all the CpG sites for each promoter region and subject.
Interestingly, we found that average methylation level at
Prom1 was decreased in AD cases compared to controls
(0.95 % vs. 5 %, p-value < 0.01) (Fig. 1b). Similarly, average
methylation level was significantly decreased within
Prom2 in AD cases compared to controls (2.80 % vs.
17.80 %, p-value < 0.001) (Fig. 1c).
CRTC1 methylation correlates with p-tau burden
Next, we aimed to correlate DNA methylation levels
with AD-related neuropathological changes recorded
from the hippocampus sections. In brief, p-tau and β-
amyloid burden were measured and averaged by using
the ImageJ software (Additional file 1: Figure S2). The
amyloid plaque score (APS) was also recorded
(Additional file 2: Table S1). Notably, the average methyla-
tion level within Prom 1 showed a strong inverse correl-
ation with p-tau deposition (rSpearman = −0.903, p < 0.001).
Although we found a correlation between Prom1 average
methylation level and β-amyloid burden (Table 1), the
p-value for this correlation did not reach the
Bonferroni-corrected significance threshold (corrected
p-value = 0.008). Likewise, average methylation level
within Prom2 was no longer correlated with p-tau de-
position and β-amyloid burden after applying the Bon-
ferroni correction (Table 1).
CRTC1 mRNA levels are downregulated in Alzheimer’s
disease hippocampus
To test if CRTC1 was differentially expressed in our co-
hort, we measured CRTC1 mRNA expression levels byTable 1 Correlation tests between CRTC1 methylation levels and Alz
AD-related changes Prom1 methylation level
Spearman coefficient r
p-tau area −0.903
averaged β-amyloid area −0.761
APS −0.761
p-tau hyperphosphorylated tau; APS amyloid plaque score
adenotes those comparisons below the Bonferroni-corrected p-value = 0.008RT-qPCR in hippocampal samples from Alzheimer’s dis-
ease (AD) cases and controls. Four samples did not pass
the RNA quality threshold and so were not included in
the experiments (see CRTC1 mRNA expression analysis
in the Methods section). Eventually, 26 AD cases were
compared to 12 controls. RT-qPCR reactions were per-
formed in triplicate for each sample and repeated twice
within independent cDNA sets. Moreover, two different
sets of primers (CRTC1-qPCR1 and CRTC1-qPCR2)
were used to increase the reliability of the experiment
(Additional file 2: Table S2). A 1.54-fold decrease in
CRTC1 mRNA levels was observed in the hippocampus
of AD cases compared to controls (p < 0.05) (Fig. 2a).
Next, a disease-staging analysis was conducted to inves-
tigate changes of CRTC1 mRNA levels across AD stages.
We found that CRTC1 mRNA levels significantly de-
creased across AD stages (p < 0.05) and post-hoc analysis
showed that CRTC1 expression was significantly reduced
at advanced stages compared to controls (p < 0.05)
(Fig. 2b).
We further tested if differences in CRTC1 mRNA ex-
pression resulted from a decrease in a particular type of
CRTC1 transcript variant. Two different CRTC1 tran-
scripts were identified in the Reference Sequence
(RefSeq) database, i.e., CRTC1 transcript variant 1
(NM_015321) and transcript variant 3 (NM_001098482),
sharing all the exons but for an additional exon (exon 3)
belonging to CRTC1 variant 3 (Fig. 2c). Due to the extra
exon 3, we were able to design a primer pair to selectively
amplify CRTC1 variant 3 (Additional file 2: Table S2),
whereas a primer pair to amplify only CRTC1 variant 1
was not able to be designed since all the exons of this vari-
ant are shared with CRTC1 variant 3. We found that levels
of CRTC1 variant 3 mRNA were not different between
AD cases and controls (p = 0.206), suggesting that signifi-
cant differences in global CRTC1 mRNA levels between
AD cases and controls might result from a reduction in
CRTC1 variant 1 mRNA.
Finally, we studied the relationship between promoter
methylation and mRNA expression for the CRTC1 gene.
We tested the correlation between DNA methylation levels
and mRNA expression levels. In order to avoid potential
bias from disease status, we tested the potential correlation
separately in two groups, controls and AD patients. Inter-
estingly, CRTC1 mRNA expression showed a trend toheimer's disease (AD)-related pathological changes
Prom2 methylation






Fig. 2 CRTC1 mRNA expression is decreased in human hippocampus in Alzheimer’s disease (AD). a The graph shows a significant 1.54-fold decrease in
CRTC1 mRNA levels in AD hippocampal samples compared to control hippocampal samples. b CRTC1 mRNA expression decreases across AD stages, as
shown when CRTC1 expression levels are sorted based on ABC score. Boxes represent percentage of CRTC1 expression relative to the geometric mean
of GAPDH and ACTB housekeeping genes expression. Bars represent the standard error of the mean. *p-value < 0.05; ** p-value < 0.005. c Two different
CRTC1 transcript variants are shown. CRTC1 variant 1 has 14 exons and CRTC1 variant 3 shares all the exons of variant 1 plus an additional exon 3. Black
boxes represent exons, arrows represent transcription start sites and white boxes denote CpG islands. CpG cytosine-phosphate-guanine
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(rSpearman = −0.949, p = 0.051) in the control group; mean-
while, no significant correlation was found between methy-
lation and expression among AD patients (rSpearman =
−0.287, p = 0.490).mRNA levels of CRTC1 downstream target genes are
altered in Alzheimer’s disease hippocampus
We also wanted to test whether CRTC1-dependent
genes were also dysregulated in our set of AD hippocam-
pal samples. To this end, we measured mRNA levels of
BDNF, c-fos, EGR4, and EGR1 by RT-qPCR in our set of
samples. Primer pairs and specific transcripts that were
amplified by RT-qPCR are shown in Additional file 2:
Table S2.
Interestingly, we found significantly decreased mRNA
levels of BDNF, EGR4, and EGR1 in AD hippocampus
compared to control hippocampus (p-value < 0.05)
(Additional file 1: Figure S4). These results are in ac-
cordance with previous reports based on AD in vitro
models, murine models and human brain. On the
contrary, c-fos mRNA expression was significantlyincreased in AD cases compared to controls in our set
of samples (p-value < 0.005) (Additional file 1: Figure S4).
Discussion
Here we report altered patterns of DNA methylation
within two distinct promoter regions of CRTC1 in the
human hippocampus affected by Alzheimer’s disease
(AD). Interestingly, DNA methylation levels are de-
creased in AD and inversely correlate with p-tau burden
in the hippocampus.
Our results indicate that important regulatory regions
for the CRTC1 gene are differentially methylated in the
AD hippocampus compared to controls. It is well known
that CRTC1 is mainly expressed in the CA1 region of
the hippocampus [8] and is essential to synaptic plasti-
city and memory consolidation [2–7]. Moreover, studies
conducted on AD mouse models highlight its relevance
to AD pathogenesis [3, 17–19] and CRTC1 protein has
been found to be downregulated in the human hippo-
campus affected by AD [19]. Thus, studying regulatory
mechanisms of CRTC1 gene expression in the human
hippocampus, one of the more vulnerable regions to AD
pathology, is of utmost interest. Our finding suggests
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might contribute to disruption of the CRTC1 gene func-
tion that was previously described in AD [19], as DNA
methylation is one of the most important epigenetic
mechanisms that regulate gene expression. Most interest-
ingly, methylation levels correlated to AD-related path-
ology changes in our cohort. In particular, a strong inverse
correlation was found between DNA methylation levels
and p-tau burden in the hippocampus (rSpearman = −0.903,
p < 0.001). It is of note that neurofibrillary tangles, which
are aggregates of p-tau protein that accumulate within
neurons, are found in the first stages of AD restricted to
the hippocampus and entorhinal cortex, while the other
hallmark of AD, β-amyloid deposition, begins to accumu-
late in the neocortex. From our data showing such a
strong correlation, we may hypothesize that altered
methylation within CRTC1 may be part of the molecular
signature of p-tau pathology in the hippocampus. Any-
how, the relationship between CRTC1 gene and p-tau
pathology merits further investigations.
We also found a mild but otherwise significant de-
crease in CRTC1 mRNA expression in AD hippocam-
pus compared to controls (Fig. 2). This finding is in
concordance with a previous report that showed both
total and phosphorylated CRTC1 protein downregula-
tion in human hippocampus affected by AD [19].
Moreover, CRTC1 mRNA expression has been found
to be decreased in other neurodegenerative conditions
and brain diseases, such as frontotemporal lobar de-
generation with progranulin mutations [34] and Down
syndrome [35] (Additional file 1: Figure S5). Down
syndrome is considered a natural model for AD, since
most people affected by Down syndrome will develop
early AD [36]. Interestingly, a significant decrease in
CRTC1 mRNA levels was shown for CRTC1 transcript
variant 1 (NM_015321) but not for CRTC1 transcript
variant 3 (NM_001098482) in Down syndrome adult
brain [35] (Additional file 1: Figure S5), which is in
line with our present work.
To understand better the relationship between
methylation and expression in our study we tested the
correlation between CRTC1 methylation and mRNA
levels. Among control hippocampus samples, we
found an inverse relationship between methylation
and expression at the Prom1 region. In other words,
lower levels of DNA methylation within Prom1
showed a trend to be correlated with higher levels of
CRTC1 mRNA (rSpearman = −0.949, p = 0.051). This
correlation is consistent with the classical model of
epigenetic regulation where loss of methylation in the
promoter region results in an increase in gene expression,
indicating that CRTC1 is probably regulated by DNA
methylation under normal circumstances. However, no
correlation between methylation and expression wasidentified among AD patients in our analysis, suggesting
that proper functioning of DNA methylation in regulating
CRTC1 expression may be disturbed in the AD context.
Finally, we show significantly decreased mRNA levels
of several CRTC1-dependent genes, such as BDNF,
EGR4, and EGR1 in AD hippocampus compared to con-
trol hippocampus (p-value < 0.05) (Additional file 1:
Figure S4), which adds consistency to the present study.
These results are in accordance with previous reports
performed on AD in vitro models, murine models and
human brain. For instance, oligomeric Aβ peptide
downregulates BDNF levels via Aβ-induced CREB
transcriptional downregulation in human neuroblast-
oma (SH-SY5Y) cells [34]. In murine models, it has
been largely demonstrated that several CRTC1-
dependent genes are downregulated in the brain tissue
affected by AD pathology, including BDNF and EGR4
[17, 18, 35]. Most interestingly, not only are BDNF
mRNA levels decreased in AD human frontal cortex
but also BDNF mRNA levels correlate with cognitive
performance of patients, assessed by Mini-Mental
State Examination scores, as was shown in a recent re-
port [36].
On the other hand, c-fos mRNA expression was sig-
nificantly increased in AD cases compared to controls in
our set of samples (p-value < 0.005) (Additional file 1:
Figure S4). Remarkably, this is in good agreement with
the results obtained from earlier studies that used AD
human hippocampus to assess c-fos expression [37-39]
but, in turn, differs from several reports that have shown
c-fos mRNA levels to be decreased in AD murine
models [17, 18, 35]. This discrepancy among the results
obtained from murine and human studies regarding c-
fos mRNA expression in the context of AD pathology
will need further research.Conclusions
In conclusion, this study provides evidence that CRTC1
methylation levels are altered in the human hippocampus
affected by AD. It also suggests that the functional relation-
ship between DNA methylation and gene expression for
CRTC1 may be altered in the AD context. Further studies
are needed to better understand the precise role that
CRTC1 methylation plays in AD pathophysiology.Additional files
Additional file 1: Figure S1. Pictures obtained at 10x from the most
representative cases showing different degrees of protein deposit. Figure
S2. Beta-amyloid and tau protein measurement in hippocampal sections.
Figure S3. Maps of the two CRTC1 regions analyzed by bisulfite sequencing
cloning in human hippocampus. Figure S4. mRNA expression levels of
CRTC1 downstream genes in human AD hippocampus compared to
controls. Figure S5. Gene Expression Omnibus (GEO) data analysis for
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Lobar Degeneration with progranulin mutations. (PDF 974 kb)
Additional file 2: Supplemental Tables. Table S1. Brain sample set
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